Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor

Area of Science:

• Oncology
• Medical Genetics
• Clinical Pharmacology

Background:

• Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
• Genetic mutations, including TP53 and KRAS, play a critical role in NSCLC pathogenesis and treatment response.
• Immune checkpoint inhibitors, such as atezolizumab, targeting the PD-L1 pathway have emerged as a significant therapeutic option for NSCLC.

Purpose of the Study:

• To investigate the association between TP53 mutations and the efficacy of atezolizumab in NSCLC patients.
• To evaluate the impact of TP53 and KRAS co-mutations on overall survival (OS) and progression-free survival (PFS) in NSCLC patients treated with atezolizumab compared to docetaxel.

Main Methods:

• Analysis of NSCLC patients from the Phase III POPLAR and OAK clinical trials.
• Kaplan-Meier analysis was employed to assess PFS and OS.
• Multivariate Cox regression analysis was used for comparative survival analysis between treatment arms.

Main Results:

• A significant improvement in OS was observed with atezolizumab compared to docetaxel in NSCLC patients with TP53/KRAS co-mutations (HR: 0.014).
• No significant difference in OS was found between atezolizumab and docetaxel for NSCLC patients with TP53 mutations alone (HR: 0.831).
• Similarly, no significant OS difference was observed for NSCLC patients with KRAS mutations alone (HR: 1.354).

Conclusions:

• Atezolizumab demonstrates potential OS benefits for NSCLC patients harboring TP53/KRAS co-mutations.
• The presence of TP53 or KRAS mutations as single mutations did not predict differential survival outcomes between atezolizumab and docetaxel.
• These findings suggest that PD-L1 inhibitors may offer survival advantages in specific molecularly defined NSCLC subgroups.